Introduction {#sec1-1}
============

OCD is a disabling psychiatric disorder with a lifetime prevalence of 2.3%. OCD patients spend an average of nearly 6 hours per day occupied with intrusive obsessions and performing compulsions or rituals.^[@ref1]^ Few OCD patients achieve full remission of symptoms. Even in patients receiving a combination of clomipramine, exposure therapy, and ritual prevention therapy, approximately one third do not respond to treatment.^2\ 3^

Many recent studies suggest stereotactic DBS as a promising treatment modality that may address OCD refractory to current therapies. DBS has been approved by the FDA for treatment of movement disorders; notably, Weaver et. al. demonstrated that DBS led to superior six-month outcomes compared to best medical therapy in advanced Parkinson disease.^[@ref4]^ DBS remains an investigational treatment for the indication of OCD, but may be used in accordance with a Humanitarian Device Exemption.^[@ref5]^

Once implanted, the parameters of the electrodes in a DBS device can be adjusted according to a patient's response to treatment. This affords a customizability that makes DBS more likely to be effective in each individual patient. By activating or deactivating specific electrodes in the implanted device, even the location of neuro-stimulation can be slightly adjusted without requiring repeat surgical intervention and re-implantation.

Meta-analysis of the many studies of OCD treatment with DBS remains limited by small sample sizes for each anatomic location, varying psychiatric and medical comorbidities of participants, and the heterogeneous approaches used to report results.^[@ref6]^ Most of these cases and studies use the Yale-Brown Obsessive-Compulsive Scale (YBOCS) to quantify the severity of patients' symptoms before and after treatment; as such, this is the best metric with which to analyze the compiled results. However, the time points at which these scores are collected vary, and they might be reported for each individual patient or in the aggregate. Moreover, the YBOCS is not sensitive to some changes in symptoms. A decrease in the number of hours spent per day on compulsions from 8 hours to 3 hours would not yield a change in score. Therefore, we aim to summarize per each location both quantitative YBOCS data and qualitative descriptions of the participants' symptoms.

Materials and Methods {#sec1-2}
=====================

PubMed was used to search for relevant literature using the terms: "obsessive compulsive disorder," "OCD," "deep brain stimulation," "DBS," and "electrical stimulation." Only studies in humans were considered. No patients were eliminated from the review on the basis of comorbid psychiatric or medical conditions. Studies not using the YBOCS as an outcome measure were not included. Cohorts of patients whose results were reported in multiple articles were counted once.

In some patients, DBS was not an effective treatment for their OCD symptoms at the first implanted location and the device was surgically removed and re-implanted elsewhere. In these situations, patients were counted as two separate trials. Patients whose devices stimulated two anatomic regions simultaneously were counted once.

Patients for whom an individual posttreatment YBOCS score was given were combined to give an overall mean reduction in YBOCS score. In order to include studies which only reported the number of patients responding to treatment (with a response being a reduction in YBOCS of 35% or more), rather than a degree of response for each individual, the percentage responders were also calculated where applicable. This threshold for determination of responders versus non-responders was the most commonly used in the literature, and is therefore used here; however, we aim to identify and qualitatively discuss non-responders with clinically relevant improvements in their symptoms of OCD.

Follow-up times among these studies varied from one month to nine years, with some patients being re-tested on the YBOCS very frequently and some only once. Therefore, the outcome measure we focus on in this review is the latest YBOCS score reported for each patient/cohort. The latest time point was not used if a significant number of patients dropped out of the study before that point. YBOCS score at earliest post-op time point tested was included when given.

Results {#sec1-3}
=======

A total of 32 articles were found in the search results. Four were eliminated from consideration due to the absence of YBOCS scores. Three papers reported on the same cohort of six patients; two papers used data from the same cohort of eight, and; another two reported on the same five patients. One additional paper was a case study of a patient included in another cohort. In total, 153 distinct patients' results were reported in these studies. Across this collection of papers, a total of nine anatomic structures were targeted ([Table 1](#table001){ref-type="table"}). Patients in whom the device was re-implanted in a different location had each of their trials counted separately. There was a total of 158 trials for these 153 patients.

The majority of studies showed a better response at the last time point as compared to the first time point (Tables 2-7).^[@ref7]^

Most patients had DBS at nucleus accumbens followed by VC/VS and the least patients had DBS at the bilateral superolateral branch of the median forebrain bundle and the bilateral basolateral amygdala ([Table 8](#table008){ref-type="table"}). The average YBOCS improvement did not seem to directly correlate with the percentile of patients responding to the intervention.

Discussion {#sec1-4}
==========

The average YBOCS reduction and percent of participants responding to therapy did not follow the same trend. This may be due to a significant difference in response in the sample despite similar intervention. But we also must consider that patients with clinical benefit who did not always meet the "responder" threshold.

Studies with fewer than 4 participants were generally more likely to have positive findings, likely due to publishing bias; we are able to see results of negative case studies in situations where stimulators were eventually re-implanted in a location that produced better results.

The question remains the same, what is the best location to implant the device? Several anatomic locations have been targeted in DBS for the indication of OCD. The VC/VS is among the most studied, followed by the nucleus accumbens.^[@ref7]^ Data is amassing for these few aforementioned locations and fortunately, new locations are being explored with both positive and negative results. Less-studied locations include the subthalamic nucleus, inferior thalamic peduncle, anterior limb of the internal capsule, anteromedial globus pallidus, superolateral branch of the median forebrain bundle, medial dorsal and ventral anterior nucleus of the thalamus, and bed nucleus of the stria terminalis.^10\ 11^

Furthermore, the studies that measured YBOCS score at multiple time points demonstrate that response to stimulation does not all occur at the beginning of therapy; rather, there is an accumulation of the effect. The percent YBOCS increase and the number of patients responding within a study tend to increase with time. In studies where the average YBOCS score did not continue to increase with time, patients still experienced clinical benefit.

Conclusions {#sec1-5}
===========

Well-controlled, randomized studies with larger sample sizes with close follow up are needed to provide a more accurate determination for placement of DBS for OCD.

###### 

Studies by anatomic site.

  B VC/VS                                                             NA                                                              ST                                                                  BN ST                                                BAIC                                                AM GP                                           ITP                                                  B SL MFB        MD/V ANT                                                BLA
  ------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------- ----------------------------------------------- ---------------------------------------------------- --------------- ------------------------------------------------------- -------------------------------------------------------
  ^[\*\*](#tfn2){ref-type="table-fn"}^Greenberg 200612 & 201013       ^[\*](#tfn1){ref-type="table-fn"}^Sturm 200321                  Mallet 200229 & 200830                                              ^[\*](#tfn1){ref-type="table-fn"}^Luyten 201633,     Anderson 200335                                     ^[\*](#tfn1){ref-type="table-fn"}^Nair 201438   ^[\*\*](#tfn2){ref-type="table-fn"}^Jimenez 200939   Coenen 201741   Maarouf 201628 ^[\*\*\*](#tfn3){ref-type="table-fn"}^   Maarouf 201628 ^[\*\*\*](#tfn3){ref-type="table-fn"}^
  Goodman 201014,                                                     Guehl 200822                                                    Fontaine 200431                                                     some patients                                        Abelson 200536                                                                                      & 201340                                                             (1st and 2nd trial)                                     (3rd trial)
  ^[\*\*](#tfn2){ref-type="table-fn"}^Vora 201215,                    Plewnia 200823                                                  ^[\*](#tfn1){ref-type="table-fn"}^Piallat 201132                    (includes                                            Chang 201037                                                                                                                                                                                                                     
  ^[\*\*](#tfn2){ref-type="table-fn"}^Fayad 201616                    Denys 201024                                                    Williams 201620 ^[\*\*\*](#tfn3){ref-type="table-fn"}^(1st trial)   ^[\*\*](#tfn2){ref-type="table-fn"}^Nuttin 201334)   Maarouf 201628                                                                                                                                                                                                                   
  Tsai 201017 & 201218                                                Huff 201025                                                     Wojtecki 2016                                                                                                            (with NAcc)                                                                                                                                                                                                                      
  Real 201619 ^[\*\*\*](#tfn3){ref-type="table-fn"}^(2nd trial)       Franzini 201026                                                                                                                                                                          ^[\*\*\*](#tfn3){ref-type="table-fn"}^(1st trial)                                                                                                                                                                                
  Williams 201620 ^[\*\*\*](#tfn3){ref-type="table-fn"}^(2nd trial)   Grant 201627                                                                                                                                                                             Luyten 201633,                                                                                                                                                                                                                   
                                                                      Real 201619 ^[\*\*\*](#tfn3){ref-type="table-fn"}^(1st trial)                                                                                                                            some patients                                                                                                                                                                                                                    
                                                                      Kohl 2016                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                      Maarouf 201628 (with ALIC)                                                                                                                                                                                                                                                                                                                                                                                                
                                                                      ^[\*\*\*](#tfn3){ref-type="table-fn"}^(1st trial)                                                                                                                                                                                                                                                                                                                                                                         

^\*^Study did not use YBOCS, eliminated

^\*\*^duplicate patients:

^\*\*\*^more than one anatomic location tried per patient. B VC/VS- Bilateral ventral capsule/ventral striatum; NA- Nucleus accumbens (bilateral and unilateral); ST- Subthalamic nucleus (bilateral); BN ST- Bed nucleus of stria terminalis; BAIC- Bilateral anterior internal capsule; AM GP- Anteromedial globus pallidus interna; ITP- Inferior thalamic peduncle; B SL MFB- Bilateral superolateral branch of the median forebrain bundle; MD/V ANT- Bilateral medial dorsal and ventral anterior nucleus of the thalamus; BLA- Bilateral basolateral amygdala.

###### 

Ventral capsule/ventral striatum.

  Study                         N.   Average YBOCS reduction at first time point   Responders at first time point   Average YBOCS reduction at latest time point   Responders at last time point
  ----------------------------- ---- --------------------------------------------- -------------------------------- ---------------------------------------------- -------------------------------
  Greenberg 200612 and 201013   26   not given at 1 month                          7/25                             38% at \>3 months                              16/26
  Tsai 201017 and 201218        4    n/a                                           n/a                              35% at x months                                2/4
  Goodman14,                    6    12 months                                     4/6                              6-9 years                                      4/6
  Vora15, Fayad16                                                                                                                                                  
  Real, trial 219               1    32% at 16 wks                                 0/1                              42% at 1 yr                                    1/1
  Williams20, trial 2           1    n/a                                           n/a                              69% at 9 months                                1/1

###### 

Nucleus accumbens.

  Study                                              N.   Average YBOCS reduction at first time point   Responders at first time point   Average YBOCS reduction at latest time point   Responders at last time point
  -------------------------------------------------- ---- --------------------------------------------- -------------------------------- ---------------------------------------------- -------------------------------
  Guehl, bilateral^[@ref22]^                         3    not given                                     n/a                              35-60% at one year. No average given           3/3
  Plewnia, unilateral^[@ref23]^                      1    25% at 4 wks                                  0/1                              21.9% at 2 years                               0/1
  Denys, bilateral^[@ref24]^                         16   46% at 32 weeks, open                         9/16                             52% at 21 months                               ?/14
  Huff, unilateral^[@ref25]^                         10   not given                                     n/a                              21% at 1 year                                  1/10
  Franzini, bilateral^[@ref26]^                      2    not given                                     n/a                              38% at 24-27 months                            2/2
  Grant, bilateral^[@ref27]^                         1    69% at 8 months                               1/1                              69-75% at 3 years                              1/1
  Real, bilateral, trial 1^19^                       1    not given                                     n/a                              7.9% at 2 years                                0/1
  Maarouf^[@ref28]^, bilateral, patient 3, trial 1   1    not given                                     n/a                              not given                                      0/1
  Kohl, bilateral                                    18   not given                                     4/18                             not given                                      6/12

###### 

Anterior limb of the internal capsule.

  Study                                                                     N.   Average YBOCS reduction at first time point   Responders at first time point   Average YBOCS reduction at latest time point   Responders at last time point
  ------------------------------------------------------------------------- ---- --------------------------------------------- -------------------------------- ---------------------------------------------- -------------------------------
  Anderson^[@ref35]^                                                        1    79.4%                                         1/1                              97.1%                                          1/1
  Abelson^[@ref36]^                                                         4    20.0% (double blind)                          1/4 (double blind)               30.25% (open)                                  2/4 (open)
  Chang^[@ref37]^                                                           1    0%                                            0/1                              11.1%                                          0/1
  Luyten^[@ref33]^, bilateral                                               4    not given                                     n/a                              20% at \>4 years                               0/4
  Luyten^[@ref33]^, bilateral, adjacent to NAcc                             2    not given                                     n/a                              26% at \>4 years                               1/2
  Luyten^[@ref33]^, bilateral, adjacent to BST                              1    not given                                     n/a                              76% at \>4 years                               1/1
  Luyten^[@ref33]^, bilateral ALIC, left adjacent to BST and right in BST   1    not given                                     n/a                              57% at \>4 years                               1/1
  Luyten^[@ref33]^, right in ALIC, left in BST                              1    not given                                     n/a                              67% at \>4 years                               1/1
  Maarouf^[@ref28]^, patients 1 and 2 (with NAcc), trial 1                  2    not given                                     n/a                              not given                                      0/2

###### 

Subthalamic nucleus.

  Study                      N.   Average YBOCS reduction at first time point                      Responders at first time point              Average YBOCS reduction at latest time point   Responders at last time point
  -------------------------- ---- ---------------------------------------------------------------- ------------------------------------------- ---------------------------------------------- -------------------------------
  Mallet et al. 2002^29^     2    81.6% at 2 weeks or 1-6 month, can't tell from table             2/2                                         n/a                                            n/a
  Mallet et al. 2008^30^     16   32.1% compared to sham stimulation, 40.6% compared to baseline   not given, but guessing from graph, 10/16   n/a                                            n/a
  Fontaine et al. 2004^31^   1    96.9% at 1 year                                                  1/1                                         n/a                                            n/a
  Williams, trial 1^20^      1                                                                                                                                                                
  Wojtecki                   1    92.3% at 3 years                                                 1/1                                         n/a                                            n/a

###### 

Bilateral medial dorsal and ventral anterior nucleus of the thalamus; bilateral superolateral branch of the median forebrain bundle; inferior thalamic peduncle; bilateral basolateral amygdala.

  Study                                                                  N.   Average YBOCS reduction at first time point   Responders at first time point   Average YBOCS reduction at latest time point   Responders at last time point
  ---------------------------------------------------------------------- ---- --------------------------------------------- -------------------------------- ---------------------------------------------- -------------------------------
  Bilateral medial dorsal and ventral anterior nucleus of the thalamus                                                                                                                                      
  Maarouf^[@ref28]^, pts 1-3 trial 2, pt 4 trial 1                       4                                                  0/4                              not given                                      0/4
  Bilateral superolateral branch of the median forebrain bundle                                                                                                                                             
  Coenen^[@ref41]^                                                       2    31.5% at 1 month                              1/2                              41.7% at 12 months                             1/2
  Inferior thalamic peduncle                                                                                                                                                                                
  Jimenez 2013^40^                                                       6    8.4% at 1 month                               0/6                              49% at 12 months                               6/6
  Bilateral basolateral amygdala                                                                                                                                                                            
  Maarouf^[@ref28]^,                                                     1    not given                                     n/a                              not given                                      0/1
  patient 3, 3rd trial                                                                                                                                                                                      

###### 

Bed nucleus of stria terminalis (BST).

  Study                                                                  N.   Average YBOCS reduction at first time point   Responders at first time point   Average YBOCS reduction at latest time point   Responders at last time point
  ---------------------------------------------------------------------- ---- --------------------------------------------- -------------------------------- ---------------------------------------------- -------------------------------
  Bilateral medial dorsal and ventral anterior nucleus of the thalamus                                                                                                                                      
  Luyten^[@ref33]^, bilateral                                            9    not given                                     n/a                              42% at \>4 years                               6/9
  Luyten^[@ref33]^, unilateral right                                     1    not given                                     n/a                              77% at \>4 years                               1/1
  Luyten^[@ref33]^, left in BST, right in IC adjacent to BST             2    not given                                     n/a                              51% at \>4 years                               2/2
  Luyten^[@ref33]^, right in BST, left in IC adjacent to BST             1    not given                                     n/a                              58% at \>4 years                               1/1
  Luyten^[@ref33]^, bilateral in prereticular zone, BST adjacent         1    not given                                     n/a                              35% at \>4 years                               1/1
  Luyten^[@ref33]^, bilateral in IC, BST adjacent                        1    not given                                     n/a                              95% at \>4 years                               1/1

###### 

Response per location.

  Location                                                               N.   Average YBOCS reduction at first time point   Responders at first time point   Average YBOCS reduction at latest time point   Responders at last time point
  ---------------------------------------------------------------------- ---- --------------------------------------------- -------------------------------- ---------------------------------------------- -------------------------------
  VC/VS                                                                  38   32%                                           11/32                            35-69%                                         24/38
  Nucleus Accumbens                                                      53   25 to 69%                                     14/36                            7.9 to 75%                                     13/31
  Anterior limb of the internal capsule                                  14   20 to 79%                                     2/6                              11 to 97%                                      7/17
  Subthalamic nucleus                                                    21   32 to 96%                                     14/20                            n/a                                            n/a
  Bilateral medial dorsal and ventral anterior nucleus of the thalamus   4    not given                                     0/4                              Not given                                      0/4
  Bilateral superolateral branch of the median forebrain bundle          2    31%                                           1 /2                             41%                                            1/2
  Inferior thalamic peduncle                                             6    8%                                            0/6                              49%                                            6/6
  Bilateral basolateral amygdala                                         1    Not given                                     n/a                              Not given                                      0/1
  Bed nucleus of stria terminalis                                        15   Not given                                     n/a                              35 to 95%                                      12/15
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